Bendamustine as a Novel Single-Agent Therapy in High Burden T-Cell Large Granular Lymphocytic Leukemia: Clinical Efficacy and STAT3 Pathway Inhibition
targeted therapyBendamustinehematologic malignancyT-cell large granular lymphocytic leukemiaSTAT3 inhibition
Highlight
Bendamustine monotherapy demonstrates considerable efficacy with a 100% overall response rate and 67% complete responses in high burden T-cell large granular lymphocytic leukemia (T-LGLL). The treatment appears effective regardless of STAT3 mutational status and shows a tolerable safety profile. Mechanistically, bendamustine directly inhibits STAT3 phosphorylation and induces apoptosis in leukemic large granular lymphocytes.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.